EGFR and neoplasm: By combining a potent EGFR binder with a medium-affine MerTK binder, the bispecific molecules will be more likely to reach the tumour microenvironment, where MerTK binding can take place to bridge tumour-associated and tumour-infiltrating macrophages with tumour cells and lead to phagocytosis in a targeted manner.